Amgen joins partnership with overseas biopharmaceutical company

You are here: Home > Latest news > Current Article

Amgen joins partnership with overseas biopharmaceutical company

By Staff Report / Wednesday, December 19th, 2018 / Comments Off on Amgen joins partnership with overseas biopharmaceutical company

Amgen announced a strategic collaboration with Swiss firm Molecular Partners to license and develop a new molecule in combination with its BiTE platform, in a deal worth up to $547 million. The molecule, called MP0310, aims to bind proteins on stromal cells to T cells, which would activate the immune system in tumors, the companies…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.